News

Pfizer and BioNTech COVID-19 vaccine more than 90% effective in early analysis

By Tyler Van Dyke
Published November 9, 2020 1:13pm ET
Add Washington Examiner on Google
Pfizer and BioNTech COVID-19 vaccine more than 90% effective in early analysis
This May 4, 2014 photo shows the Pfizer logo on the exterior of a former Pfizer factory, in the Brooklyn borough of New York. The pharmaceutical giant reports quarterly financial results on Tuesday, July 29, 2014. | (AP Photo/Mark Lennihan)

Pfizer and BioNTech announced Monday morning that one of its vaccine candidates has a more than 90% effectiveness in preventing COVID-19.

“Today is a great day for science and humanity,” said Pfizer CEO Alberta Bourla. “The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.”

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 Markets Pfizer Vaccines